Mengting Chen

Dr. Mengting Chen

orcid

Research Focus & Metrics

Academic Career Length

5Years (2022-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
6 June 2022 in International Journal of Pharmaceutics
Verified
Journal Article
Closed access
MJMei Jiang
Mei Jiang
XFXiaocui Fang
Xiaocui Fang
LMLilusi Ma
Lilusi Ma
MLMingpeng Liu
Mingpeng Liu
MCMengting Chen
Mengting Chen
CWChen Wang
Chen Wang

12 September 2023 in Pharmaceutics
Verified
Journal Article
Open access
PDF file
MCMengting Chen
Mengting Chen
XFXiaocui Fang
Xiaocui Fang
RDRong Du
Rong Du
JMJie Meng
Jie Meng
JLJingyi Liu
Jingyi Liu
CWChen Wang
Chen Wang
Chronic myeloid leukemia (CML) is recognized as a classic clonal myeloproliferative disorder. Given the limited treatment options for CML patients in the accelerated phase (AP) and blast phase (BP), there is an evident need to develop new therapeutic strategies. This has the potential to improve outcomes for individuals in the advanced stages of CML. A promising therapeutic target is Wilms’ tumor 1 (WT1), which is highly expressed in BP-CML cells and plays a crucial role in CML progression. In this study, a chemically synthesized nucleus-targeting WT1 antagonistic peptide termed WIP2W was identified. The therapeutic implications of both the peptide and its micellar formulation, M—WIP2W, were evaluated in WT1+ BP-CML cell lines and in mice. The findings indicate that WIP2W can bind specifically to the WT1 protein, inducing cell cycle arrest and notable cytotoxicity in WT1+ BP-CML cells. Moreover, subcutaneous injections of M—WIP2W were observed to significantly enhance intra-tumoral accumulation and to effectively inhibit tumor growth. Thus, WIP2W stands out as a potent and selective WT1 inhibitor, and the M—WIP2W nanoformulation appears promising for the therapeutic treatment of refractory CML as well as other WT1-overexpressing malignant cancers.